Single Peptides · Exact presentation
AICAR · 50 mg Vial
AICAR · 50 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 50 mg presentation, the reference concentration of 16.7 mg/mL mathematically corresponds to 2.994 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 16.7 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.167 mg at this concentration.
Standard / Gradual Approach (3 mL = ~16.7 mg/mL)
The source chart summarizes “1 mg–3 mg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (3 mL = ~16.7 mg/mL)
| Week/Phase | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 1,000 mcg (1 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 2,000 mcg (2 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 3,000 mcg (3 mg) | 18 units (0.18 mL) |
Reconstitution Steps
For a 50 mg presentation, the reference concentration of 16.7 mg/mL mathematically corresponds to 2.994 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 16.7 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.167 mg at this concentration.
Advanced Protocol (Higher Doses)
The source chart summarizes “1 mg–3 mg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Advanced Protocol (Higher Doses)
| Week/Phase | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 2,000 mcg (2 mg) | 12 units (0.12 mL) |
| Weeks 3–6 | 3,000 mcg (3 mg) | 18 units (0.18 mL) |
| Weeks 7–12 | 5,000 mcg (5 mg) | 30 units (0.30 mL) |
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It is studied in cellular bioenergetics, mitochondrial function, substrate metabolism, or stress signaling. The specific molecular target depends on the compound.
Potential Benefits & Side Effects
A biochemical effect should not be extrapolated to a clinical outcome. Formulation, concentration, and studied population are decisive.
Source trail
Scientific references and source discovery
- PeptideDosages — exact AICAR · 50 mg Vial entrysecondary-structure
- PubMed — literature search for AICARprimary-discovery
- ClinicalTrials.gov — study search for AICARtrial-registry
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference